{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-012687","form_type":"8-K","ticker":"PALI","cik":"0001357459","company_name":"PALISADE BIO, INC.","filed_at":"2025-09-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.807779+00:00","generated_at":"2026-05-17T07:54:13.144495+00:00","sec_items":["5.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Palisade Bio adopts Phantom Unit Plan, grants 10M cash-settled units, amends exec employment agreements","bullets":["Phantom Unit Plan approved; up to 10,000,000 cash-settled phantom units may be granted.","CEO J.D. Finley granted 323,400 Phantom Units; CMO Mitchell Jones 289,000; SVP Ryker Willie 137,600.","Board Chair granted 64,400 units; each other independent director granted 37,600 units.","Executives' phantom units vest quarterly over 3 years; directors vest annually over 3 years.","Amended employment agreements: CEO base $575K, CMO $440K, SVP Finance $298.5K, with enhanced severance."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-012687","json":"https://secwatch.observer/filing/0001493152-25-012687.json","markdown":"https://secwatch.observer/filing/0001493152-25-012687.md","text":"https://secwatch.observer/filing/0001493152-25-012687.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357459/000149315225012687/0001493152-25-012687-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357459/000149315225012687/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T07:54:13.144495+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}